- DEBUT study met the primary endpoint, demonstrating superior patient global satisfaction with Buvidal® vs daily sublingual buprenorphine
- Buvidal® showed significantly better effects on patient's quality of life, burden of treatment, and other secondary endpoints
- Buvidal® is the first and only long-acting opioid dependence treatment to show superiority vs daily sublingual therapy in controlled, head-to-head studies
PR Newswire
LUND, Sweden, Nov. 26, 2019